Active, not recruitingPhase 1NCT05876780
A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)
Studying Beta-sarcoglycan-related limb-girdle muscular dystrophy R4
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarepta Therapeutics, Inc.
- Principal Investigator
- Medical DirectorSarepta Therapeutics, Inc.
- Intervention
- SRP-9003(genetic)
- Enrollment
- 6 enrolled
- Eligibility
- 4-50 years · All sexes
- Timeline
- 2022 – 2028
Study locations (2)
- Nationwide Children's Hospital, Columbus, Ohio, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05876780 on ClinicalTrials.govOther trials for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4
Additional recruiting or active studies for the same condition.
See all trials for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4 →